Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eisai Ltd ADR (OP: ESALY )

61.51 UNCHANGED
Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 61.51
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 61.51
Today's Range 61.51 - 61.51
52wk Range 36.88 - 73.90
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023. 
Via InvestorPlace
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
 
Via Benzinga

Performance

YTD
-7.29%
-7.29%
1 Month
N/A
N/A
3 Month
-5.46%
-5.46%
6 Month
+54.74%
+54.74%
1 Year
+25.63%
+25.63%

More News

Read More
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
Via Benzinga
Daily Stock Analysis: Eisai
Via Talk Markets
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
Via Benzinga
Why Anavex Life Sciences Stock Bolted Higher in January
Via The Motley Fool
Lecanemab Receives Priority Review Status in Japan
From Eisai
Via JCN Newswire
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
From Eisai
Via JCN Newswire
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
From Eisai
Via JCN Newswire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?
Via The Motley Fool
In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug
Via Investor's Business Daily
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
Via The Motley Fool
1 Green Flag and 1 Red Flag for Biogen
Via The Motley Fool
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
From Eisai
Via JCN Newswire
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich
Via The Motley Fool
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?
Via The Motley Fool
Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill
Via Benzinga
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
Via Benzinga
Lecanemab Alert: What Would Alzheimer’s Drug Approval Mean for Biogen (BIIB) Stock?
Via InvestorPlace
Biogen Could Get A Second Alzheimer's OK — But Will Wild Card Medicare Bite?
Via Investor's Business Daily
1 Stock Defying the Downturn to Buy, and 1 to Avoid
Via The Motley Fool
Top Picks For 2023: Catalyst Pharmaceuticals
Via Talk Markets
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Via Benzinga
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.